Gossypol


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:33283869IVR2 - 5 mg/kg 2 - 5 mg/kgAffects neuronal signalingNeurological endocrine-mediated perturbations
IVR2 - 5 mg/kg 2 - 5 mg/kgInduce behavioral changesNeurological endocrine-mediated perturbations
IVR2 - 5 mg/kg 2 - 5 mg/kgDecreased brain weights in offspringDevelopmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations
IVR2 - 5 mg/kg 2 - 5 mg/kgCauses inflammationImmunological endocrine-mediated perturbations
IVR2 - 5 mg/kg 2 - 5 mg/kgDecreased body weights in offspringDevelopmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations
IVR5 mg/kg 5 mg/kgDecreased body weightsMetabolic endocrine-mediated perturbations
IVR2 - 5 mg/kg 2 - 5 mg/kgAffects neuronal densityNeurological endocrine-mediated perturbations
IVR5 mg/kg 5 mg/kgIncreased brain weightsNeurological endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.